Susann Patschan, Constantin Remus, Inga Claus, Meike Hoffmeister, Oliver Ritter, Daniel Patschan
{"title":"脊柱炎的代谢组学。","authors":"Susann Patschan, Constantin Remus, Inga Claus, Meike Hoffmeister, Oliver Ritter, Daniel Patschan","doi":"10.1186/s41927-025-00546-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aim: </strong>Spondyloarthritides (SpA) are common entities of the inflammatory rheumatic type. There are still 3 relevant problems in everyday clinical practice: early disease detection, cardiovascular risk assessment, and less so, disease activity measurement. Metabolomics allows the quantification of a large number of small-molecule substances from biological samples.</p><p><strong>Methods: </strong>The following databases were searched for references: PubMed, Web of Science, Cochrane Library, Scopus. The period lasted from 1973 until 2024.</p><p><strong>Results: </strong>Finally, 14 analyses were identified. Most studies have evaluated patients with established disease. Some studies were able to un-mask metabolomic characteristics of certain forms of SpA. Approaches that utilize an integrative view of several metabolites in combination with general patient characteristics appear to be quite promising. Such approaches are suitable, for example, for assessing activity in psoriatic arthritis (PsA) or evaluating cardiovascular risk in individuals with psoriatic disease.</p><p><strong>Conclusions: </strong>Metabolomics are helpful in identifying new diagnostic and predictive parameters in SpA, so far mainly in PsA. An almost consistent limitation of the studies to date is the inclusion of patients with already manifest disease.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"92"},"PeriodicalIF":2.5000,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12285033/pdf/","citationCount":"0","resultStr":"{\"title\":\"Metabolomics in spondylarthritis.\",\"authors\":\"Susann Patschan, Constantin Remus, Inga Claus, Meike Hoffmeister, Oliver Ritter, Daniel Patschan\",\"doi\":\"10.1186/s41927-025-00546-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and aim: </strong>Spondyloarthritides (SpA) are common entities of the inflammatory rheumatic type. There are still 3 relevant problems in everyday clinical practice: early disease detection, cardiovascular risk assessment, and less so, disease activity measurement. Metabolomics allows the quantification of a large number of small-molecule substances from biological samples.</p><p><strong>Methods: </strong>The following databases were searched for references: PubMed, Web of Science, Cochrane Library, Scopus. The period lasted from 1973 until 2024.</p><p><strong>Results: </strong>Finally, 14 analyses were identified. Most studies have evaluated patients with established disease. Some studies were able to un-mask metabolomic characteristics of certain forms of SpA. Approaches that utilize an integrative view of several metabolites in combination with general patient characteristics appear to be quite promising. Such approaches are suitable, for example, for assessing activity in psoriatic arthritis (PsA) or evaluating cardiovascular risk in individuals with psoriatic disease.</p><p><strong>Conclusions: </strong>Metabolomics are helpful in identifying new diagnostic and predictive parameters in SpA, so far mainly in PsA. An almost consistent limitation of the studies to date is the inclusion of patients with already manifest disease.</p>\",\"PeriodicalId\":9150,\"journal\":{\"name\":\"BMC Rheumatology\",\"volume\":\"9 1\",\"pages\":\"92\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-07-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12285033/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Rheumatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s41927-025-00546-3\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Rheumatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s41927-025-00546-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景和目的:脊椎关节炎(SpA)是常见的炎症性风湿病类型。在日常临床实践中仍存在3个相关问题:早期疾病检测、心血管风险评估和较少的疾病活动度测量。代谢组学允许对生物样品中的大量小分子物质进行定量分析。方法:检索PubMed、Web of Science、Cochrane Library、Scopus等数据库。这一时期从1973年持续到2024年。结果:最终确定了14项分析。大多数研究评估的是已确诊疾病的患者。一些研究能够揭示某些形式的SpA的代谢组学特征。利用几种代谢物的综合观点与一般患者特征相结合的方法似乎很有前途。例如,这些方法适用于评估银屑病关节炎(PsA)的活动性或评估银屑病患者的心血管风险。结论:代谢组学有助于发现新的SpA诊断和预测参数,目前主要用于PsA。迄今为止,研究的一个几乎一致的局限性是纳入了已经表现出疾病的患者。
Background and aim: Spondyloarthritides (SpA) are common entities of the inflammatory rheumatic type. There are still 3 relevant problems in everyday clinical practice: early disease detection, cardiovascular risk assessment, and less so, disease activity measurement. Metabolomics allows the quantification of a large number of small-molecule substances from biological samples.
Methods: The following databases were searched for references: PubMed, Web of Science, Cochrane Library, Scopus. The period lasted from 1973 until 2024.
Results: Finally, 14 analyses were identified. Most studies have evaluated patients with established disease. Some studies were able to un-mask metabolomic characteristics of certain forms of SpA. Approaches that utilize an integrative view of several metabolites in combination with general patient characteristics appear to be quite promising. Such approaches are suitable, for example, for assessing activity in psoriatic arthritis (PsA) or evaluating cardiovascular risk in individuals with psoriatic disease.
Conclusions: Metabolomics are helpful in identifying new diagnostic and predictive parameters in SpA, so far mainly in PsA. An almost consistent limitation of the studies to date is the inclusion of patients with already manifest disease.